Compare Citius Pharmaceuticals Inc (CTXR) vs TORM plc (TRMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs TORM plc — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $20.01M), while TORM plc trades at $28.3 (market cap $2.93B). The key difference: TORM plc is far larger — about 146.4× Citius Pharmaceuticals Inc's market cap, and TORM plc pays a 9.77% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | TRMD | |
|---|---|---|
Market Cap | $20.01M | $2.93B |
Sector | Health | Technology |
52-Week High | $1.82 | $34.87 |
52-Week Low | $0.48 | $18.77 |
Enterprise Value | $16.23M | $3.82B |
Dividend Yield | — | 9.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
TRMD trades at $29.49 with a neutral daily change. The stock shows strong fundamentals with a P/E of 8.57, net income margin of 24.41%, and ROE of 15.62%, though recent Q1 2026 EPS missed expectations. Technical indicators are bearish overall, with support at $28 and resistance at $30. Recent news highlights strong Q1 2026 results and a dividend of $0.70 per share.
The outlook is positive with 100% analyst buy ratings and robust cash flow, but risks include earnings volatility and market sentiment. The stock offers value through dividends and growth potential, yet investors should monitor earnings consistency and macroeconomic factors affecting the tanker market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →
